Medicus Pharma Ltd. (MDCX) · Nov 19, 2026 · Delisting
Conditional compliance — $2.5M equity requirement; next test is the December 31, 2026 report
Medicus Pharma’s Nasdaq compliance is restored after financings and debt exchange, but the listing remains conditional on its December 31 equity test.
Medicus is a cash-burning, precision-oncology-led biotech trying to advance CD228V while keeping its financing structure intact; its September 30 filing showed negative shareholders’ equity and $31.9 million of operating cash use year to date. The immediate listing threat is paused, not eliminated. Nasdaq lifted the market-value deficiency after the company qualified under the alternative $2.5 million shareholders’ equity standard.
| Item | November 2026 | Requirement / reference |
|---|---|---|
| Equity financing (Press release) | $4.25M | |
| Debt exchanged for preferred shares (Press release) | $10.5M | |
| Nasdaq shareholders’ equity threshold (Item 8.01) | $2.5M |
The fix was financial engineering rather than operating progress. The company raised approximately $4.25 million in equity and exchanged $10.5 million of debt for preferred shares, actions that were already disclosed in the November 16 transaction filing; this notice mainly confirms Nasdaq’s acceptance of that structure.
The key weakness is that compliance is conditional and the balance-sheet cushion is thin. Medicus must demonstrate continued compliance in its report for the period ending December 31, 2026, or it may again face delisting proceedings. 〔0〕
Bottom line: This removes an immediate Nasdaq overhang and preserves the listing for now, but it does not materially improve the underlying biotech execution story. The real test is whether the financing-driven equity improvement survives through year-end.
FY 2026 report for period ending December 31, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!